

Pharmaceutical Pipeline – Key Events in 2020*

Potential Approvals US/EU

ERLEADA® (apalutamide)	– Metastatic castrate sensitive prostate cancer (TITAN) (EU) ✓
SPRAVATO™ (esketamine nasal spray)	– Major Depressive Disorder with Active Suicidal Ideation and Intent (US/EU)
IMBRUVICA®	– Frontline CLL combo w/Rituximab (Young and Fit) (E1912) (US ✓ / EU)
TREMFYA®	– Psoriatic Arthritis (US ✓ / EU)
DARZALEX®	– Frontline Multiple Myeloma transplant (CASSIOPEIA) (EU) ✓ – Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (COLUMBA) (US / EU) ✓ – Relapsed Refractory multiple myeloma w/carfilzomib/dex (AMGEN) (US)
INVOKANA®	– Treatment of Diabetic Kidney Disease in adults with T2DM (EU) ✓
VAC52150 Monovalent Ebola vaccine	– Ebola Vaccine (EU) ✓
rilpivrine long acting maintenance	– HIV (EU)

Planned Submissions US/EU

Ciltacabtagene Autoleucel (BCMA CAR-T)	– Multiple Myeloma (US)
ponesimod	– Monotherapy for multiple sclerosis (US / EU) ✓
SPRAVATO™ (esketamine nasal spray)	– Major Depressive Disorder with Active Suicidal Ideation and Intent (EU) ✓
DARZALEX®	– Amyloidosis (ANDROMEDA) (US / EU) – Relapsed Refractory Multiple Myeloma w/PomDex (US / EU) – Relapsed Refractory multiple myeloma w/carfilzomib/dex (AMGEN) (US) ✓
IMBRUVICA®	– Frontline CLL combo w/rituximab (Young & Fit) (EU) ✓
Paliperidone Palmitate 6-month	– Schizophrenia (US / EU)
XARELTO®	– Infrainguinal revascularized PAD (US)
UPTRAVI® IV	– Pulmonary arterial hypertension (US)
Amivantamab (EGFR/cMET)	– Non Small Cell Lung Cancer (US)

Potential Clinical Data Presentations

Phase 3

XARELTO®	– Peripheral Artery Disease (VOYAGER PAD) ✓
DARZALEX®	– Amyloidosis (ANDROMEDA) ✓ – Refractory Multiple Myeloma w/PomDex (APOLLO)

Phase 2

TREMFYA®	– Crohn's Disease (GALAXI)
seltorexant	– Insomnia (ISM2005) ^
Ciltacabtagene Autoleucel (BCMA CAR-T)	– Multiple Myeloma (MMY2001)

✓ = Achieved

^ Joint presentation with Minerva Neurosciences.